Abstract B101: Tumor-selective inhibition of active RAS in pancreatic ductal adenocarcinoma
Urszula N. Wasko(Revolution Medicines (United States)), Kenneth P. Olive(Columbia University Irving Medical Center), Julien Dilly(Massachusetts Institute of Technology), Yingyun Wang(Revolution Medicines (United States)), Robert H. Vonderheide(University of Pennsylvania), Andrea Califano(Columbia University Irving Medical Center), Ben Z. Stanger(Cancer Research Institute), Mallika Singh(Revolution Medicines (United States)), Margo Orlen(UPMC Hillman Cancer Center), Channing J. Der(University of North Carolina at Chapel Hill), Stephanie Chang, Steven A. Sastra(National Center on Addiction and Substance Abuse at Columbia University), Andrew J. Aguirre(Broad Institute), Carmine F. Palermo(Columbia University Irving Medical Center), Lorenzo Tomassoni(Columbia University Irving Medical Center), Bianca J. Lee(Revolution Medicines (United States)), Marie Ménard(University of California, San Francisco), Jingjing Jiang(Revolution Medicines (United States)), Kristina Drizyte‐Miller(University of North Carolina at Chapel Hill)
Cited by 1
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal
|Immunity|1998|1.1k
Activated Kras and <i>Ink4a/Arf</i> deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
|Genes & Development|2003|1k